MWA Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

MWA Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.85M	Buy	4,143 +927	+29%	+$432K	1.01%	30
2025 Q4	$1.46M	Buy	3,216 +18	+0.6%	+$7.76K	0.81%	38
2025 Q3	$1.25M	Sell	3,198 -2,061	-39%	-$861K	0.69%	44
2025 Q2	$2.34M	Buy	5,259 +334	+7%	+$154K	1.43%	22
2025 Q1	$2.39M	Buy	4,925 +1,739	+55%	+$810K	1.66%	18
2024 Q4	$1.28M	Buy	3,186 +603	+23%	+$280K	0.85%	39
2024 Q3	$1.2M	Sell	2,583 -2,018	-44%	-$969K	0.8%	43
2024 Q2	$2.16M	Buy	4,601 +2,491	+118%	+$1.08M	1.54%	16
2024 Q1	$882K	Sell	2,110 -99	-4%	-$41.9K	0.64%	54
2023 Q4	$899K	Buy	2,209 +1,011	+84%	+$373K	0.74%	45
2023 Q3	$417K	Buy	+1,198	New	+$419K	0.4%	76

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MWA Asset Management's VRTX Position: Q1 2026 in Review

MWA Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 29% in Q1 2026, buying an estimated $432K and bringing the position to 4,143 shares worth $1.85M. The position accounts for 1.01% of the portfolio, ranked #30.

MWA Asset Management first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.39M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

MWA Asset Management held 4,143 shares of Vertex Pharmaceuticals worth $1.85M as of Q1 2026.
MWA Asset Management bought 927 Vertex Pharmaceuticals shares in Q1 2026, an estimated $432K.
Vertex Pharmaceuticals made up 1.01% of MWA Asset Management's portfolio in Q1 2026, its #30 holding.
MWA Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
MWA Asset Management's Vertex Pharmaceuticals position peaked at $2.39M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on MWA Asset Management's 13F filing for Q1 2026, filed 7 May 2026.